Circulating Tight-junction Proteins are Potential Biomarkers for Blood-Brain Barrier Function in a Model of Neonatal Hypoxic/Ischemic Brain Injury

Axel Erik Andersson (axel.andersson@gu.se)
University of Gothenburg

Carina Mallard
University of Gothenburg Institute of Neuroscience and Physiology: Goteborgs universitet Institutionen for neurovetenskap och fysiologi

Carl Joakim Ek
University of Gothenburg Institute of Neuroscience and Physiology: Goteborgs universitet Institutionen for neurovetenskap och fysiologi

Research

Keywords: Biomarkers, blood–brain barrier, hypoxia/ischemia, neonatal, tight-junctions

DOI: https://doi.org/10.21203/rs.3.rs-90299/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background** Neonatal encephalopathy often leads to lifelong disabilities with limited treatments currently available. The brain vasculature is an important factor in many neonatal neurological disorders but there is a lack of diagnostic tools to evaluate the brain vascular dysfunction of neonates in the clinical setting. Measurement of blood-brain barrier tight-junction proteins have shown promise as biomarkers for brain injury in the adult. Here we tested the biomarker potential of tight-junctions in the context of neonatal brain injury.

**Methods** The levels of TJ-proteins (occluding, claudin-5, and zonula occludens protein 1) in both blood plasma and cerebrospinal fluid (CSF) as well as blood-brain barrier function via $^{14}$C-sucrose (342 Da) and Evans blue extravasation were measured in a hypoxia/ischemia brain-injury model in neonatal rats.

**Results** Time-dependent changes of occludin and claudin-5 levels could be measured in blood and CSF after hypoxia/ischemia with males generally having higher levels than females. The levels of claudin-5 in CSF correlated with the severity of the brain injury at 24h post-hypoxia/ischemia. Simultaneously, we detected early increase in blood-brain barrier-permeability at 6 and 24h after hypoxia/ischemia.

**Conclusions** Levels of circulating claudin-5 and occludin are increased after hypoxic/ischemic brain injuries and blood-brain barrier-impairment and have promise as early biomarkers for cerebral vascular dysfunction and as a tool for risk assessment of neonatal brain injuries.

Impact Statement

- BBB dysfunction following neonatal hypoxia/ischemia is likely in part due to the loss of tight-junction proteins from cerebral blood vessels. BBB breakdown release tight junction proteins and BBB function may be assessed by measuring these proteins in the circulation.
- This is the first study which investigates tight-junction proteins in the CSF and correlate to levels in circulation in a neonatal animal model of brain injury.
- Elevated levels of blood-brain barrier-derived tight-junction proteins Claudin-5 and Occludin can be detected in the circulation at several time-points in a rat-model for neonatal HI, signifying the proteins potential as biomarkers for the brain vascular dysfunction in neonates.

Background

Neonatal encephalopathy is a syndrome characterised by neurological dysfunction presenting as e.g. seizures and respiratory difficulties (1, 2). Neonates that are diagnosed with neonatal encephalopathy (NE) are, if they survive, at high risk of developing life-long and permanent neurodevelopmental disabilities(3). Although hypothermia has been shown to be a beneficial treatment under certain circumstances, since it has to be initiated within six hours and can only be implemented in some of the neonates, with a number needed to treat of around eight, novel or adjunctive treatments are needed(4, 5).
A key step in the development of new treatments is diagnostic tools enabling early diagnosis and/or monitoring of injury progression. The aetiology underlying brain injury in the newborn is complex and is likely to involve many factors, making early diagnosis very difficult(6). The most commonly used early clinical tools to assess neonatal NE include cord blood gas analyses(7), Apgar and Sarnat scoring systems(8). However, these methods have a low predictive value for the subsequent brain injury(9). The resulting brain injuries are typically visualised by advanced imaging methods such as MRI and CT-scans(10), techniques that are both expensive and have a relatively low availability, in terms of both equipment and skilled personnel, in many countries.(11) This is important to note as it has been estimated that as many as 96% of neonates affected by NE are born in low- and middle-income countries(12). There is a clinical need for better and affordable diagnostics of neonatal brain injuries that would enable early risk assessment and intervention as well as monitoring of injury development. Putative biomarkers for neuronal damage following NE would be a valuable diagnostic tool to predict long-term outcomes but has the drawback that they are usually measurable only after the injury has manifested(13).

The brain vasculature is a central factor in many human neonatal neurological disorders, such as intracranial haemorrhages and neonatal stroke(14), and the blood-brain barrier (BBB) is disrupted early in the disease process(15-20). A biomarker that reflects the state and function of the neonatal brain vasculature could be a powerful predictor for brain injury, considering that studies in rats have shown that the dysfunction of the BBB mirrors the severity of hypoxic/ischemic (HI)-injuries(15, 16). Additionally, assessment of BBB function is of importance for the success of treatments that are directed at the brain. The capillary endothelial cells of the cerebrovasculature are connected by continuous complexes of tight-junction (TJ) proteins, which restrict passage between the brain and the bloodstream, thus maintaining the integrity of the BBB and function of the brain(21). Previous studies in adults have shown that TJ proteins are shed from the BBB and cerebral vasculature and enters the circulation in a model of adult stroke in rats(22), in humans following stroke(23) as well as after intracranial haemorrhage(24). Furthermore, studies in cultured cerebral endothelial cells and in vivo adult rats have shown that the BBB is dysfunctional after hypoxia/ischemia(25-28) and that a TJ-barrier is formed early in development has been shown both in a range of mammals including humans (29-32).

Given that TJ proteins have been suggested as potential biomarkers in adult brain injury models, we hypothesised that BBB related proteins could be detected in blood and cerebrospinal fluid (CSF) after neonatal HI. In this study we focused on three of the key TJ-proteins in the brain endothelium, claudin-5 (CLDN5), occludin (OCLN) and zonula occludens protein 1 (ZO-1). CLDN5 is an integral transmembrane TJ protein expressed by brain vascular endothelial cells adhering neighbouring cells together and sealing up the paracellular space between the cells of the BBB(33) with structural support from the intracellular scaffold protein ZO-1(34) while OCLN acts as a regulator of TJ-function and remodelling(35). In order to study the role of TJ proteins in neonatal brain injury we used a well-established model wherein a HI brain-injury is induced in post-natal day (PND) 7 rats by ligation of the left common carotid artery combined with a period of hypoxia(36), the brains of PND 7 rats approximates near-term human infants(37). This model has been developed to approximate cerebral hypoxia-ischemia believed to be part of the aetiology
of infants affected by NE\(^{(38)}\). Circulating TJ-proteins in blood plasma and cerebrospinal fluid (CSF), brain injury and BBB function after injury were determined.

**Methods**

**Animals**

Postnatal day 7 (PND7) Wistar rat pups were bred in-house at the Laboratory for Experimental Biomedicine of Gothenburg University (parents were sourced from Janvier Labs, Le Genest-Saint-Isle, France) and maintained under normal housing conditions with a 12h light/dark cycle and free access to water and standard laboratory fodder. Animals of both sexes and different litters were used for the experiments and care was taken to minimise the number of animals used and to maintain an even sex-balance in all experimental and control groups. All experiments were approved by the Gothenburg Committee of the Swedish Animal Welfare Agency (Application nos. 663/17) and performed in accordance with the ARRIVE guidelines. A total of 104 animals were used throughout the study.

**Hypoxia-ischemia (HI)**

PND7 rats were anaesthetised with isoflurane (3.5-5%, Vetmedic, Stockholm, Sweden) in a 50/50 oxygen/nitrogen mixture, placed on their backs and a small incision was made in the neck to gain access to the carotid artery. A suture was placed permanently around the left carotid artery and the incision sealed with Vetbond tissue adhesive (3M, MN, USA). Surgery typically lasted for 3-5 min. Following surgery, pups were allowed to recover in their home cage together with their mother for 1h. Subsequently, operated pups were placed in a 36 °C chamber. The chamber was perfused first with humidified air for 10 min followed by 8% oxygen for 1h and then by humidified air for 10 min. After the hypoxic exposure, pups were returned to their home cages. Control animals was subjected to sham-surgery (anaesthesia and incision) but no hypoxia. During all procedures, animals were monitored for vitals (i.e. breathing and skin-colour); every animal in the study survived the surgery and hypoxia.

**Sample collection and processing**

For all time-points after HI (i.e. 6h, 24h and 5 days) injured and control animals were euthanised with a lethal overdose of pentobarbital. Cerebrospinal fluid was collected from the cisterna magna through glass capillaries as described previously\(^{(39)}\) and blood was collected by cardiac puncture with ethylenediaminetetraacetic acid (EDTA)-treated syringes. CSF was checked for blood contamination as previously described\(^{(40)}\) and samples discarded when contamination detected (detection limit about 0.2%). Blood samples were centrifuged at 2000 xg for five min to separate the plasma. Samples were placed on dry ice after collection and long-term stored in -80 °C freezer until analysed. Whole brains (excluding the cerebellum and brain stem) were collected and immersed in cold 6% buffered formaldehyde (Histofix; Histolab, Gothenburg, Sweden) at 4 °C for 24h before processing for paraffin embedding.
Caspase-3 activity assay

The activity of cleaved caspase-3 at 6h (n=7) and 24h (n=7) after HI was measured using a fluorometric assay based on an earlier study(41). Whole brain hemispheres where homogenised in cold RNase free phosphate-buffered saline (PBS) and sonicated in cold RNase free PBS containing 2% protease inhibitor cocktail (Sigma-Aldrich, MO, USA) and 10 mM EDTA. Aliquots were centrifuged at 10 000 xg for 15 min in 4 °C and some supernatant were used for bicinchoninic acid concentration measurements. For caspase-3 activity, 20 μl supernatant were incubated with 80 µl extraction buffer composed of a buffer base (50 mM Tris, 100 mM NaCl, 5nM EDTA, 1 mM egtazic acid, pH 7.3) and 0.2% 3-(3-cholamidopropyl)dimethylammonio-1-propanesulfonate, 1% protease inhibitor cocktail, and 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich) on a 96 well plate for 15 min in room temperature (RT). 100 µl assay buffer made up of buffer base plus 4mM dithiothreitol, 1 mM PMSF and 25 µM caspase-3 substrate (Peptides International, KY, USA) were added to the wells before the plate was read for 1h at 37 °C with 2 min intervals on a SpectraMax Gemini EM microplate reader (Molecular Devices, CA, USA) set to excitation wavelength 380 nm and emission wavelength 460 nm. Endpoint readings were made before and after 10 µl of 10 µM free 7-amino-4-methylcoumarin (AMC) (Peptides International) and the V_max was calculated from the linear part of the curve, caspase-3 activity was expressed as pmol AMC/min·mg caspase-3.

Enzyme-linked immunosorbent assay (ELISA)

Plasma- and CSF-samples were analysed using pre-coated ELISA kits for tight-junction proteins CLDN5 (Nordic BioSite. Stockholm, Sweden), OCLN (Cusabio, Wuhan, China), and ZO-1 (Cusabio) as per the manufacturer’s instructions. Plasma was diluted 20 times and CSF 10 times. In short, standards, CSF and plasma-samples were diluted in sample diluent buffer and incubated on ELISA-plates pre-coated with the antibody. After incubations with a biotinylated secondary antibody, horseradish peroxidase (HRP)-avidin, 3,3',5,5'-Tetramethylbenzidine substrate, and a stop-solution the optical density was determined with a Spectramax Plus microplate reader (San Jose, CA, USA) set to 450 nm with 540 nm wavelength-correction (OCLN and ZO-1) or 450 nm (CLDN5). The protein concentration was determined from the resulting standard-curve. CSF and plasma from the same animals were analysed for both CLDN5 and OCLN, n=7-8 for all time-points. Due to some differences between ELISA-plates, all data were normalised to the median of time-matched controls analysed on the same plate.

Blood-brain barrier assessment

The blood-brain barrier permeability was measured using radiolabelled sucrose as described by our group earlier(39). For all time points after HI; 6h (n =9), 24h (n=8), 5 days (n=9), injured and PND7 and PND12 control animals (n=6 for each age) were injected intraperitoneally (i.p.) with two μCi 14C-sucrose (American Radiolabelled Chemicals, MO, USA) in saline (100 μl injection volume). Thirty min later, they were euthanised with a lethal overdose of pentobarbital. Blood was collected through cardiac puncture using a heparinised syringe and centrifuged at 2000 xg for five min to separate plasma. Choroid plexuses
were removed and whole cerebellum and brain stem as well as left and right hippocampus, cortex and
striatum/thalamus were dissected and collected into pre-weighed scintillation vials and then re-weighed.
500µl of Solvable (PerkinElmer, MA, USA) was added to all samples and they were incubated overnight in
a 40 °C oven to dissolve the tissue. After checking that all tissues were solubilised, samples were left to
cool down to RT, mixed with 10 mL Ultima Gold scintillation cocktail (PerkinElmer) and left for 60 min in
darkness. The radioactivity in each sample was determined by liquid scintillation counting in a Tri-Carb
4910TR (PerkinElmer) and calculated as cpm/mg sample after background corrections. Brain/plasma
sucrose concentration ratios were used as a measurement of BBB-permeability as previously described
after correcting for residual blood space in brain.(42) These concentration ratios were calculated as a
measure of BBB permeability in each region and ratios in the left (injured) hemisphere was compared to
the right hemisphere as previously outlined(15).

BBB-disruption after HI was also tested using injections of Evans blue (EB) dye, a dye that binds to
albumin in the blood and thus should be regarded as a high-molecular marker opposed to sucrose (43).
4% EB dissolved in PBS were injected i.p. (4 µl per g body weight) 6h post-HI (n=3) and in control animals
(n=3). After 1h, animals were euthanised with a lethal overdose of pentobarbital and transcardially
perfused with saline and 6% buffered formaldehyde. Whole brains (excluding the cerebellum and brain
stem) were collected and immersed in cold 6% buffered formaldehyde at 4 °C for 24h before they were
embedded in 4% agarose and cut in 100 µm thick sections in a Leica 1200 VT vibratome (Leica
Biosystems, Wetzlar, Germany).

Sections were mounted in water-based CC/Mount (Sigma) and imaged at 680 nm, the wavelength in
which emitted fluorescence from EB peaks(44). EB-extravasation into the brain were quantified in cortical
micrographs from injured animals (n=3) and controls (n=3). Images were segmented via thresholding,
creating binary images of EB+-area which were measured and calculated as a percentage of the entire
image area.

Measurement of brain blood-vessel area

Entire hemispheres of CLDN5-stained fluorescent paraffin-sections of brains collected five days after HI
and controls (n=5 per group) were imaged with a tiling and stitching function. Two levels (700 µm apart)
at mid-hippocampal level were imaged per animal and analysed with an in-house developed macro for
the Fiji-build(45) of ImageJ(46) that utilises difference of Gaussian to eliminate all background while
preserving all vessel information to accurately measure the area of blood vessels in an image. Briefly,
entire CLDN5-stained brain hemispheres were imaged in a fluorescent microscope (Additional file 1a); the
process is shown in a smaller selection of the image (Additional file 1b) for clarity. A copy of the image
was subjected to Gaussian blur with sigma = 10 (Additional file 1c). The blurred image was subtracted
from the original and threshold applied with Fiji’s “analyse particle”-tool to filter out any eventual debris
so only marked blood vessels remained (Additional file 1d). The resulting vessel-image were then
superimposed on the original image (Additional file 1) to confirm accurate vessel labelling. Blood vessel
area was quantified in both injured and uninjured hemispheres by first outlining a region of interest (ROI)
delineating the entire cortex and hippocampus and measure the total tissue area. Then the area of marked blood vessels within the ROI was determined and the percentage of blood vessel area of the total area in the hemisphere was calculated. Averages were calculated from the two mid-hippocampal levels per animal. Investigators were blinded to treatment groups during analysis.

**Immunohistochemistry and microscopy**

Paraffin-embedded brains were cut in seven µm thick coronal sections at six levels and 40 sections apart with a microtome, starting at what corresponds to approximately -2.5 mm from bregma in an adult rat. For 3, 3'-diaminobenzidine (DAB) immunohistochemistry (IHC), sections were deparaffinised by 30 min incubation at 65 °C followed by xylene, and decreasing gradients of ethanol (100% to 70%), and rinsed in dH₂O. Antigens were retrieved by boiling in citric buffer (10 mM, pH 6) before endogenous peroxidases were blocked with 3% H₂O₂. Unspecific binding was blocked by incubating sections in serum-free protein block (Agilent Dako, CA, USA) for 1h in room-temperature (RT) followed by 4 °C overnight incubation with primary antibodies (the used antibodies were directed against platelet endothelial cell adhesion molecule (CD31) microtubule-associated protein-2 (MAP-2), CLDN5, and OCLN, diluted in PBS/0.05% Tween20 (see Table 1). After incubation with the appropriate biotinylated secondary antibodies (Vector Laboratories CA, USA) for 1h at RT, the staining was enhanced by treatment with Vectastain Elite ABC HRP kit (Vector Laboratories). Finally, sections were dehydrated in gradients of ethanol (70-100%) followed by xylene and mounting in Pertex xylene-based mounting media (Histolab). For fluorescent IHC; deparaffinization, antigen retrieval, blocking, and antibody-incubations were performed as described above before mounting with ProLong Gold Antifade with or without 4’,6-diamidino-2-phenylindole/DAPI (ThermoFisher, MA, USA). Between all staining steps, sections were washed three times with PBS/0.05% Tween20 (except for after blocking). DAB-stained sections were imaged and photographed with a BX60 microscope equipped with a TH4-200 light-source using the cellSens software (Olympus, Tokyo, Japan) and fluorescently stained sections were examined with a Zeiss Axio Imager .Z2 equipped with Colibri 7 LED-light-source and a MRc AcioCam using the ZEN Blue software (Zeiss, Oberkochen, Germany).

**Table 1. The antibodies used for immunohistochemistry.**

| Primary antibodies          | Secondary antibodies          | Manufacturer (primary antibody) |
|-----------------------------|-------------------------------|---------------------------------|
| **Mouse-anti-MAP2 (1/1000)** | Biotinylated horse-anti-mouse (1/250) | Sigma-Aldrich, M4403            |
| **Mouse-anti-rat CLDN5 (1/1000)** | Goat-anti-mouse AF 594 (1/250) | ThermoFisher, 4C3C2             |
| **Rabbit-anti-rat OCLN (1/500)** | Goat-anti-rabbit AF 488 (1/250) | ThermoFisher, 71-1500           |
| **Rat-anti-mouse CD31 (1/100)** | Donkey-anti AF 594 (1/250) | BD Pharmingen, MEC 13.3          |
DAB-stained sections were imaged and photographed with a BX60 microscope equipped with a TH4-200 light-source using the cellSens software (Olympus, Tokyo, Japan) and fluorescently stained sections were examined with a Zeiss Axio Imager Z2 equipped with Colibri 7 LED-light-source and a MRc AcioCam using the ZEN Blue software (Zeiss, Oberkochen, Germany).

**Quantification of CLDN5 expression in entire brain hemispheres**

CLDN5 immunoreactivity was quantified in brightfield micrographs of entire brain sections from all time points after HI. For each image, separate ROIs were drawn around the left and right hemisphere and the images were, similarly to the EB-studies above, segmented via thresholding into binary images with CLDN5-positive areas marked. CLDN5 immunoreactivity was calculated as a percentage of the entire hemisphere area.

**Brain injury and tight-junction protein level**

To test correlation of tight-junction protein levels and degree of brain injury, brains, CSF and blood plasma were collected from HI-animals (n = 12) 24 post-HI. The plasma and CSF were analysed for CLDN5 and OCLN with ELISA as described above while the brains were embedded in paraffin and sectioned to assess the brain injury. Grey matter tissue loss in the injured hemisphere was determined in brightfield-micrographs of coronal brain-sections stained for the neuron- and dendrite-marker Microtuble-associated protein 2 (MAP2). The images were analysed in ImageJ by delineating regions of interests encompassing the entire injured or uninjured hemispheres and measuring the MAP2 positive immunoreactivity in each hemisphere by investigators blinded to which groups and animals the images belonged to. The percentage of tissue loss in each level were calculated from the MAP2-positive area with this formula: 
\[
\frac{(\text{MAP2}_{\text{uninjured}} - \text{MAP2}_{\text{injured}})}{\text{MAP2}_{\text{uninjured}}} \times 100
\]
(47). In all animals, the analysis was performed at six levels encompassing the entire brain and the mean tissue loss of all levels was used in the correlation analysis.

**Statistics and graphs**

Statistical analyses were made using GraphPad Prism version 8.00 for Windows (GraphPad Software, CA, USA). We used one-way ANOVA with Dunnett’s multiple comparison test, and Pearson’s correlations. The Benjamin-Hochberg method (FDR 0.1) was used to control for multiple correction problems when multiple t-tests were conducted. Specific tests are stated in each Figure legend. Principal component analysis was made using Qlucore Omics explorer software (Lund, Sweden) where the built-in statistics module was used to test differences between sexes on variables (unpaired t-test). Images were processed in the Fiji build(45) of ImageJ(46), figures were designed in Affinity Photo and Designer (Serif Europe, West Bridgford, United Kingdom). The variance of the data in the text of the results-section is presented as mean ± SD.
Results

**HI induced caspase-3 activation in the injured brain hemisphere**

In this model of neonatal HI, the combination of left carotid artery ligation and global hypoxia produces brain injury and tissue loss in the left hemisphere\(^{(36)}\). To confirm injury in all animals the activity of caspase-3, a hallmark of apoptosis, was measured in homogenates from both injured (left) and uninjured (right) hemisphere of HI and control animals (Additional file 2). Virtually no caspase-3 activity was detected in either the uninjured hemispheres of HI-animals nor in hemispheres of the controls while a significant increase in caspase-3 activity was seen in the injured hemisphere of HI-animals 6h after HI compared to the uninjured hemisphere (p=0.0344) or control animals (p=0.028). Caspase-3 activity was further increased in the left hemisphere at 24h after HI compared to 6h after HI (p=0.0087), controls (p=0.0027) as well as the uninjured hemisphere (p=0.0060). The range of caspase activity for the 6h and 24h post-HI groups were 3-77 and 10-950 pmol AMC/min x mg protein, respectively.

**HI-injury resulted in time-dependent increased levels of circulating tight-junction proteins CLDN5 and OCLN in cerebrospinal fluid and plasma and ZO-1 in CSF.**

Levels of CLDN5, OCLN and ZO-1 were measured in CSF and plasma with ELISA at 6, 24h and 5 days after HI and all time-points were compared with a control group collected and analysed at the same time and on the same ELISA-plate. CLDN5 and OCLN proteins were detected in all samples with levels ranging between ~41 to 1300 pg/ml (plasma), ~100 to 2400 pg/ml (CSF) for OCLN and ~2 to 30 ng/ml (plasma), ~30 to 53 ng/ml (CSF) for CLDN5. Elevated CLDN5-levels were detected in CSF (Fig. 1d) at 24h post-HI (p=0.0082), while plasma-concentrations (Fig. 1c) were higher than controls at 6h (p=0.0427). There were no difference at later times between HI and controls. Similarly, OCLN concentration in CSF (Fig. 1b) was raised at 6h (p=0.0026) after HI while the levels were higher in plasma (Fig. 1a) of HI-animals at 24h (p=0.0285). Measured values (mean ± SD) for CLDN5 and OCLN in blood plasma and CSF are available in Additional file 3. ZO-1 was only detectable in 47% of CSF samples. We found great variability in levels between plasma with as high as 2000pg/mL in one animal but no differences were measured across groups at any time point after HI (Additional file 4).

Principal component analysis (PCA) was performed (dimension reducing) as means of discriminate analysis with the input of all above measured variables for OCLN and CLDN5. HI and control animals were grouped into three distinct groups at 6h and 24h after HI (Fig. 2a) whereas at 5 days post-HI (Fig. 2b), no clustering of control vs HI animals was apparent. To test effect of sex on levels of TJ-proteins we performed unpaired t-test between male and female animals pooling all samples within all injured and within all control animals, adjusting for time as a factor. Male rats (n=10) showed significantly higher levels of OCLN in plasma (p=0.035) and CLDN5 in CSF (p=0.036) than female rats (n=11), control animals (males n=7, females n=9) had no sex-differences in plasma OCLN (p=0.91) or CSF CLDN5 (p=0.19) (Fig. 2c). In HI-animals, the average amount of OCLN in plasma were ~700 pg/ml for males and ~400 pg/ml for females, for CLDN5 in CSF the numbers were ~36 ng/ml for males and ~26 ng/ml for females.
Dynamic changes in BBB function following HI in neonates

To determine changes in BBB function over time after HI we performed measurements of BBB-permeability in different brain regions (i.e. hippocampus, cortex, and striatum/thalamus) by quantifying the permeability for $^{14}$C-labelled sucrose across the BBB. We previously showed (15) that the BBB in the uninjured hemisphere is not altered. We confirmed this for the 6h (controls n=5, HI n=5) and 5-day time-points (controls n=5, HI n=5) (Additional file 5) corroborating with caspase-3 activation (Additional file 2). Increased BBB permeability occurred in the ipsilateral hemisphere at 6h post-HI in the cortex (1.10±0.05, p=0.0007), hippocampus (1.07±0.08, p=0.0277), and striatum/thalamus (1.05±0.05, p=0.0111) and was also significantly higher at 24h in both hippocampus (1.12±0.12, p=0.0486) and cortex (1.18±0.28, p=0.0474) while the striatum/thalamus appeared unaltered (1.01±0.07, p=0.7624) (Fig. 3a). Mentionable is that these concentration ratios are probably somewhat affected by the edema occurring in the injured hemisphere after the insult suggesting that the magnitude of BBB permeability increase is likely marginally higher than what these ratios reflect. The concentration ratios 5d post-HI was significantly lower in the injured cortex (0.88±0.12, p=0.0191) as well as in the entire injured hemispheres (0.91±0.10, p=0.0303) (Fig. 3b).

BBB disruption following HI were confirmed via assessment of EB-bound albumin extravasation into the brain parenchyma in brain sections. Animals injected with EB at 6h post-HI showed fluorescence in the cortex of the injured hemispheres (fig. 3d) while the uninjured hemispheres showed weak fluorescence restricted to blood vessels (fig. 3e). Control animals injected with EB and not perfused showed distinct blood vessels-restricted fluorescence (fig. 3f) while animals not injected with EB showed no signal. Extravasated EB encompassed 51.1±8.4% of the total area in images from the injured hemisphere, significantly compared to images from the uninjured hemisphere (6.3±1.9%, p=0.0002) and controls (5.8±1.6%, p=0.0002) where the EB was restricted to blood vessels.

The vascular density of the brain is not altered five days after HI

Since the cerebrovascular area, the effective surface area for exchange between blood and brain, can affect measurements of BBB-permeability we developed an in-house written macro for blood vessel analysis of CLDN5 (as a vascular marker) immunolabelled sections. We specifically wanted to estimate cerebrovascular area at later times after injury since there is loss of brain tissue and potentially blood vessels. Sections from brains 5 days post-HI were used to calculate the area of blood vessels in the brain. Two levels were analysed per animal and results averaged (Fig. 3c). For this analysis, the hippocampus and cortex results were combined in each hemisphere. In control animals 2.01±0.64% of the brain area was comprised of vessels while in HI animals vessels comprised 1.53±0.37% of the uninjured hemisphere and 2.05±0.61% in the injured hemisphere. No significant differences were detected between control animals and either hemisphere of injured animals (p>0.05).

CLDN5 immunoreactivity is not altered in the cerebral blood vessels of neonatal rats
Given that there are reports of changes in TJ-protein immunoreactivity following hypoxia/ischemia and hypoxia alone (28, 48), we performed double immunofluorescent labelling of CLDN5 (Fig. 4a) together with blood vessel marker CD31 (platelet endothelial cell adhesion molecule) in paraffin brain-sections collected at all time points after HI (time chosen given BBB changes). In control animals, we found robust immunoreactivity of TJ-proteins in vessels in all brain regions examined including the cortex, hippocampus, and striatum/thalamus, while no labelling was detectable in parenchyma of the brain. Likewise, in animals after HI we found immunolabelling of blood vessels across all brain regions including MAP2-negative regions with no apparent changes compared to control animals. CLDN5 immunoreactivity was quantified in DAB-developed sections for CLDN5 only. No significant differences in CLDN5-coverage were seen between HI (n=9) and control animals (n=6) (p>0.05), or between the injured and uninjured hemisphere in HI-animals (p>0.05), at any time-point (n=3 per time point) when CLDN5-immunoreactivity was quantified in entire stained brain hemispheres (Fig. 4b).

CLDN5 levels in CSF correlates with brain-injury severity 24h after HI

The correlation between circulating TJ-protein levels and brain injury severity were investigated 24h after HI by analysing plasma- and CSF-levels of TJ:s and simultaneously quantifying the loss of grey matter in the brain of the same animal. This time-point was chosen based on the earlier ELISA-results (Fig 1). The average brain tissue loss in the HI-group (n=12) varied from 24.7 to 59.9% (one representative level is shown in Fig. 5b and d, respectively). By using the Pearson correlation on the levels of circulating TJ-proteins and the tissue loss percentages (Fig. 5a), the levels of CLDN5 in CSF was found to significantly (p=0.016) correlate with the severity of the grey matter tissue loss (r=0.702). No correlation was observed between the loss of grey matter and levels of CLDN5 in plasma (r=-0.001) nor OCLN in CSF (r=0.060) or plasma (r=0.039).

Discussion And Conclusions

The brain vasculature is a central component in HI associated brain injuries that appears damaged early in the injury process with studies indicating loss of BBB function in response to neonatal HI(15, 49). However, diagnostic tools to evaluate brain vascular dysfunction in neonates in an early, affordable, accessible, and reliable manner are lacking. We show elevated levels of OCLN and CLDN5 in both CSF and plasma in response to loss of blood-brain barrier function and that CLDN5 levels in CSF correlates with brain-injury severity. Our data indicate that loss of BBB function is likely, at least partially, due to molecular impairment of endothelial tight-junctions after HI injury. The data suggest that the intermembrane TJ-proteins CLDN5 and OCLN are putative blood or CSF biomarkers for cerebral vascular dysfunction and brain damage in neonates.

The cerebrovasculature is specialised in that it harbours a range of barrier and transport mechanism not found in peripheral blood vessels, which compartmentalises the brain from the rest of the body so that brain cells can function in a controlled environment and provides protection for the brain from potential harmful blood solutes. These mechanisms are normally referred to as the blood-brain barrier and an
essential part are the tight-junctions localised to the luminal side of the inter-endothelial cleft forming a
physical barrier between blood plasma and brain(50). The protein architecture of these junctions is
complex with both inter- and intracellular elements. In this study we focused on two intracellular TJ-
proteins, CLDN5, which are specific and essential for normal BBB function (51) and, OCLN, which plays a
role in BBB modulation(52). We made measurements of both BBB function together with measurements
of TJ-proteins in both CSF and plasma in order to interpret data in an integrated manner.

We found time-dependent changes in both BBB function and TJ-proteins levels following HI. Detection of
Evans blue in the injured region of HI-injured animals confirmed BBB-disruption following HI and the BBB
permeability was acutely increased following HI in rat neonates in agreement with earlier rat studies(16,
20, 53) and with a similar time line to what we have seen in mice(15). Clinical data show about five times
higher albumin CSF/blood ratios of babies diagnosed with NE indicative of BBB damage also in human
newborns, although such ratios should be interpreted with caution (49). Overall, the greatest changes in
BBB-opening appeared to be in the cortex, the region most affected in this HI-model of rats(54). However,
we also see a correlation between severity of injury and BBB opening in the different brain regions, similar
to the earlier mouse study(15).

OCLN in CSF were significantly increased 6h after HI while levels in plasma increased at 24h. Levels of
CLDN5 on the other hand were elevated in plasma at 6h post-HI, while levels in CSF were higher than
normal at 24h. Levels of CLDN5 and OCLN appeared to be normalised in both plasma and CSF five days
after HI. CLDN5 was more concentrated than OCLN in both plasma and CSF. High levels of ZO-1 could
only be measured in the CSF in some of the animals and was not detectable in plasma, thus it appears
that ZO-1, being an intracellular protein, is not as readily released into the blood after BBB damage.
Ischemia has been shown to induce matrix metalloproteinase(MMP)-mediated disruption of TJ-
proteins(55), thus altering the cellular distribution of CLDN5 and OCLN in neonatal mice(14) and adult
rats(56) and seemingly releasing some TJ-proteins into the circulation.

Pan et al(22) measured the levels of tight-junction proteins in blood up to 4.5h after the induction of
ischemic stroke via middle-cerebral artery occlusion (MCAO) in adult rats and saw a significant increase
of circulating OCLN and a molecular loss of OCLN from cerebral microvessels at 4.5h post-MCAO while
reporting no differences in blood-CLDN5 levels. A follow up study yielded similar results in adult rats after
MCAO as well as showing that blood OCLN was elevated in human stroke patients within 24h and up to
3d after stroke onset, the levels of OCLN in blood was reduced after treatment with normobaric hyperoxia
which inhibits MMP-9 activity(57). While we cannot directly compare our results to their studies as they
have utilised adult animals in another model, it is evident that focal stroke and MCAO leads to an
increase in blood OCLN levels earlier than in our neonatal model where we see a peak in blood OCLN 24h
after HI.

The raised levels of TJ-proteins in both CSF and plasma indicate that BBB dysfunction after neonatal HI
injury is likely to be at least partially due to direct molecular damage to the endothelial TJ:s. Intriguingly,
the raised levels of circulating OCLN and CLDN5 did not occur at the same time after HI showing that
these proteins although normally intimately localised do not appear to be released into these biofluids in the same manner. The exact cause of this unclear, but it has been shown that OCLN and CLDN5 are affected differently in the early ischemic stroke stages with the former being degraded by MMP:s and the latter instead redistributed via the membrane protein caveolin-1 (58). The complex linking of CLDN5 and OCLN to domains of intercellular adapter proteins is different, as reviewed by Piontek et al. (59), and may also play a role in their release from tight-junctions.

Furthermore, we tested whether levels TJ proteins could reflect severity of injury, choosing the 24h time-point since our results indicated particularly raised levels of CLDN5 in CSF at this time. This showed that levels of CLDN5 in CSF correlated with the severity of brain injury while OCLN levels and plasma CLDN5 showed no correlation. Human studies on circulating TJ proteins have only been made in adults, which makes direct comparisons with our results more difficult, but there are some common observations. Kazmierski et al. (23) measured TJ proteins in serum after ischemic stroke and found that levels of circulating CLDN5 and OCLN could predict clinical deterioration as a result of haemorrhagic transformation up to 4.5h after stroke onset, with the most sensitive measurement being the CLDN5/ZO-1 ratio. Comparing TJ-levels in blood and CSF as well as BBB-disruption between controls and a cohort of patients with intracranial haemorrhage (ICH), Jiao et al. (24) showed that CSF, but not serum, levels of TJ proteins are sensitive predictors for BBB-damage after ICH. These studies and our results implies that the levels of circulating TJ-proteins indeed corresponds to the severity of vascular and tissue injury, and BBB-disruption following ischemic events in the brain. Their results also agree with our finding that circulating CLDN5 was more abundant than OCLN.

Taken together our study shows that even a moderate opening of BBB in this model results in raised levels of TJ-proteins at early time points after HI which suggests that TJ-proteins are released into the circulation in the early stages of BBB-damage and could act as biomarkers for vascular integrity and possibly also be useful as brain injury predictor. Our results also indicate a sex difference where males have higher levels of circulating OCLN in plasma and CLDN5 in CSF. This resonates well with previous studies that have shown that there is a tendency for male rats to have graver injuries than females after neonatal HI in an almost identical model to the one employed in this study (60) and it is also known that male human infants have a higher risk for NE (61). Since our study was not specifically designed to investigate sex differences and analysis involved pooling samples from different time-points, further studies would be needed for confirmation of results. CLDN5 and OCLN showed different patterns of release into biofluids indicating that measuring both of them in tandem would give a better interpretation of injury to the brain vasculature after HI. We therefore performed discriminate analysis showing that HI-animals grouped together and were separate from controls up to 24h after HI when the levels of CLDN5 and OCLN in both plasma and CSF were analysed together.

While TJ proteins seem to have potential as standalone biomarkers for neonatal cerebral vasculature dysfunction, many studies, as reviewed in Douglas-Escobar and Weiss (62), Chalak (63), and Lv (13), have focused on biomarkers related to inflammation and brain injury. As the reviews state, the best course of action will most likely be to develop a panel of different markers in conjunction with diagnosis and other
monitoring methods of neonatal brain injuries. Promising biomarker-candidates for assessing NE brain injuries include neuronal injury markers such as Tau and neurofilament light proteins(64), brain injury marker protein S100B(65), and inflammation-related cytokines like IL-6 and IL-8(66). The levels of circulating TJ-proteins in blood from human stroke patients has been shown to positively correlate with the levels of S100B(23) and we saw a correlation between white matter tissue loss and the levels of CLDN5 in CSF. We therefore believe circulating TJ-proteins have promise as a marker for vascular dysfunction, which, in combination with markers for inflammation and injury, would increase the discriminatory, and predictive power of a marker panel for NE brain injuries.

Intriguingly, our results indicated that BBB function does not normalise at later times after HI but instead there is an apparent decrease in permeability below normal levels five days after the insult. One explanation could be that there is loss of blood vessels in the brain tissue after HI, which would reduce the surface area for exchange and thus reduce flux between blood and brain. We therefore estimated the cerebrovascular area at 5 days after HI, which showed that the tissue remaining in the injured hemisphere did not differ in vascular area compared to control animals. Thus, loss of blood vessels unlikely explains the difference in measured BBB permeability. We previously demonstrated an upregulation of both CLDN5 and OCLN genes following neonatal HI injury in mice (15), which could be a response to normalise barrier function and might underlie the decrease in barrier permeability we observed in the present study. Brain blood flow, measured between 3 to 48h, in the PND 7 rat HI-model have also shown that that cortical blood flow in this model is reduced not until 48h after injury, indicating that HI could lead to alterations in the vascular physiology(67). Speculatively, the time-dependent changes in BBB permeability, increased entry rate in the acute phase (6-24h) followed by decreased entry rate later (5 days) could influence the efficacy of drug treatment in relation to their time of administration time. A limitation of the study is the large inter-animal variability in injury, inherent to this model-system of neonatal HI (68). Furthermore, brain injury is limited to the hypoxic/ischemic hemisphere, unlike human infants which often develop more generalised brain injuries(69).

List Of Abbreviations

AMC - 7-amino-4-methylcoumarin
BBB – Blood-brain barrier
CD31 - Platelet endothelial cell adhesion molecule (CD31)
CLDN5 – Claudin-5
CSF – Cerebrospinal fluid
DAB - 3, 3’-diaminobenzidine
EB- Evans blue
Declarations

Ethics approval and consent to participate

All animal experiments were approved by the Gothenburg Committee of the Swedish Animal Welfare Agency (Application nos. 663/17) and performed in accordance with the ARRIVE guidelines.

Consent for publication

Not applicable.

Availability of data and materials

The data behind the conclusions of this study are available from the corresponding author upon reasonable request.
Competing interests

The Authors declares that there is no conflict of interest with respect to the research, authorship, or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Rune och Ulla Amlövs Stiftelse (EAA), Herbert och Karin Jacobsons Stiftelse (EAA), Swedish Research Council (VR-2017-01409 – CM), Åhlen Foundation (CM), Public Health Service at the Sahlgrenska University Hospital (ALFGBG-722491 - CM), Swedish Brain Foundation (FO2019-0270 - CM), Cerebral Palsy Alliance Australia (CJE), Stroke-Riksförbundet (CJE), and Wilhelm and Martina Lundgren Foundations (CJE).

Authors' contributions

CJE and CM conceived and designed the study and supervised all aspects of the study. EAA and CJE performed animal experiments. EAA performed ex vivo experiments, image- and statistical- analyses. Results were interpreted by EAA, CJE, and CM. EAA wrote the initial draft of the paper with input, revisions, and approval from all authors. Correspondence to be addressed to CJE.

Acknowledgements

The authors want to acknowledge the staff at the Centre for Cellular Imaging at the University of Gothenburg for providing assistance in fluorescent imaging and Nazanin Shahbazi for the technical assistance she provided to the Evans blue-experiments.

References

1. Molloy EJ, Bearer C. Neonatal encephalopathy versus Hypoxic-Ischemic Encephalopathy. Pediatric research. 2018;84(5):574-.
2. Aslam S, Strickland T, Molloy EJ. Neonatal Encephalopathy: Need for Recognition of Multiple Etiologies for Optimal Management. Front Pediatr. 2019;7:142-.
3. Douglas-Escobar M, Weiss MD. Hypoxic-ischemic encephalopathy: a review for the clinician. JAMA pediatrics. 2015;169(4):397-403.
4. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. The Cochrane database of systematic reviews. 2013;2013(1):Cd003311.
5. Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet (London, England). 2005;365(9460):663-70.
6. Glass HC. Hypoxic-Ischemic Encephalopathy and Other Neonatal Encephalopathies. Continuum (Minneapolis, Minn). 2018;24(1, Child Neurology):57-71.
7. Armstrong L, Stenson BJ. Use of umbilical cord blood gas analysis in the assessment of the newborn. Archives of disease in childhood Fetal and neonatal edition. 2007;92(6):F430-4.

8. Goswami IR, Whyte H, Wintermark P, Mohammad K, Shivananda S, Louis D, et al. Characteristics and short-term outcomes of neonates with mild hypoxic-ischemic encephalopathy treated with hypothermia. Journal of perinatology : official journal of the California Perinatal Association. 2020;40(2):275-83.

9. Ruth VJ, Raivio KO. Perinatal brain damage: predictive value of metabolic acidosis and the Apgar score. BMJ (Clinical research ed). 1988;297(6640):24-7.

10. Natarajan N, Pardo AC. Challenges in neurologic prognostication after neonatal brain injury. Seminars in perinatology. 2017;41(2):117-23.

11. Mariani G, Kaszniea-Brown J, Paez D, Mikhail MN, D HS, Bhatla N, et al. Improving women's health in low-income and middle-income countries. Part II: the needs of diagnostic imaging. Nuclear medicine communications. 2017;38(12):1024-8.

12. Lee AC, Kozuki N, Blencowe H, Vos T, Bahalim A, Darmstadt GL, et al. Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. Pediatric research. 2013;74 Suppl 1(Suppl 1):50-72.

13. Lv H, Wang Q, Wu S, Yang L, Ren P, Yang Y, et al. Neonatal hypoxic ischemic encephalopathy-related biomarkers in serum and cerebrospinal fluid. Clinica chimica acta; international journal of clinical chemistry. 2015;450:282-97.

14. Baburamani A, Ek CJ, Walker D, Castillo-Melendez M. Vulnerability of the developing brain to hypoxic-ischemic damage: contribution of the cerebral vasculature to injury and repair? Frontiers in Physiology. 2012;3(424).

15. Ek CJ, D'Angelo B, Baburamani AA, Lehner C, Leverin AL, Smith PL, et al. Brain barrier properties and cerebral blood flow in neonatal mice exposed to cerebral hypoxia-ischemia. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2015;35(5):818-27.

16. Muramatsu K, Fukuda A, Togari H, Wada Y, Nishino H. Vulnerability to cerebral hypoxic-ischemic insult in neonatal but not in adult rats is in parallel with disruption of the blood-brain barrier. Stroke. 1997;28(11):2281-8; discussion 8-9.

17. Svedin P, Hagberg H, Sävman K, Zhu C, Mallard C. Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci. 2007;27(7):1511-8.

18. Tu Y-F, Tsai Y-S, Wang L-W, Wu H-C, Huang C-C, Ho C-J. Overweight worsens apoptosis, neuroinflammation and blood-brain barrier damage after hypoxic ischemia in neonatal brain through JNK hyperactivation. J Neuroinflammation. 2011;8:40-.

19. Yang D, Sun YY, Nemkul N, Baumann JM, Shereen A, Dunn RS, et al. Plasminogen activator inhibitor-1 mitigates brain injury in a rat model of infection-sensitized neonatal hypoxia-ischemia. Cerebral cortex (New York, NY : 1991). 2013;23(5):1218-29.
20. Ferrari DC, Nesic OB, Perez-Polo JR. Oxygen resuscitation does not ameliorate neonatal hypoxia/ischemia-induced cerebral edema. Journal of neuroscience research. 2010;88(9):2056-65.

21. Berndt P, Winkler L, Cording J, Breitkreuz-Korff O, Rex A, Dithmer S, et al. Tight junction proteins at the blood-brain barrier: far more than claudin-5. Cellular and molecular life sciences : CMLS. 2019;76(10):1987-2002.

22. Pan R, Yu K, Weatherwax T, Zheng H, Liu W, Liu KJ. Blood Occludin Level as a Potential Biomarker for Early Blood Brain Barrier Damage Following Ischemic Stroke. Scientific reports. 2017;7:40331.

23. Kazmierski R, Michalak S, Wencel-Warot A, Nowinski WL. Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients. Neurology. 2012;79(16):1677-85.

24. Jiao X, He P, Li Y, Fan Z, Si M, Xie Q, et al. The Role of Circulating Tight Junction Proteins in Evaluating Blood Brain Barrier Disruption following Intracranial Hemorrhage. Disease markers. 2015;2015:860120.

25. Mark KS, Davis TP. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. American journal of physiology Heart and circulatory physiology. 2002;282(4):H1485-94.

26. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2007;27(4):697-709.

27. Liddelow SA, Dziegielewska KM, Ek CJ, Habgood MD, Bauer H, Bauer H-C, et al. Mechanisms that determine the internal environment of the developing brain: a transcriptomic, functional and ultrastructural approach. PLoS One. 2013;8(7):e65629-e.

28. Page S, Munsell A, Al-Ahmad AJ. Cerebral hypoxia/ischemia selectively disrupts tight junctions complexes in stem cell-derived human brain microvascular endothelial cells. Fluids and barriers of the CNS. 2016;13(1):16.

29. Ballabh P, Hu F, Kumarasiri M, Braun A, Nedergaard M. Development of tight junction molecules in blood vessels of germinal matrix, cerebral cortex, and white matter. Pediatric research. 2005;58(4):791-8.

30. Bauer HC, Bauer H, Lametschwandtner A, Amberger A, Ruiz P, Steiner M. Neovascularization and the appearance of morphological characteristics of the blood-brain barrier in the embryonic mouse central nervous system. Brain research Developmental brain research. 1993;75(2):269-78.

31. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468(7323):562-6.

32. Ek CJ, Dziegielewska KM, Stolp H, Saunders NR. Functional effectiveness of the blood-brain barrier to small water-soluble molecules in developing and adult opossum (Monodelphis domestica). The Journal of comparative neurology. 2006;496(1):13-26.
33. Wen H, Watry DD, Marcondes MCG, Fox HS. Selective decrease in paracellular conductance of tight junctions: role of the first extracellular domain of claudin-5. Mol Cell Biol. 2004;24(19):8408-17.
34. Rodgers LS, Beam MT, Anderson JM, Fanning AS. Epithelial barrier assembly requires coordinated activity of multiple domains of the tight junction protein ZO-1. Journal of Cell Science. 2013;126(7):1565.
35. Van Itallie CM, Fanning AS, Holmes J, Anderson JM. Occludin is required for cytokine-induced regulation of tight junction barriers. Journal of Cell Science. 2010;123(16):2844.
36. Rice JE, 3rd, Vannucci RC, Brierley JB. The influence of immaturity on hypoxic-ischemic brain damage in the rat. Annals of neurology. 1981;9(2):131-41.
37. Hagberg H, Ichord R, Palmer C, Yager JY, Vannucci SJ. Animal models of developmental brain injury: relevance to human disease. A summary of the panel discussion from the Third Hershey Conference on Developmental Cerebral Blood Flow and Metabolism. Developmental neuroscience. 2002;24(5):364-6.
38. Hagberg H, Peebles D, Mallard C. Models of white matter injury: comparison of infectious, hypoxic-ischemic, and excitotoxic insults. Mental retardation and developmental disabilities research reviews. 2002;8(1):30-8.
39. Mottahedin A, Smith PL, Hagberg H, Ek CJ, Mallard C. TLR2-mediated leukocyte trafficking to the developing brain. Journal of leukocyte biology. 2017;101(1):297-305.
40. Habgood MD, Knott GW, Dziegielewska KM, Saunders NR. The nature of the decrease in blood-cerebrospinal fluid barrier exchange during postnatal brain development in the rat. The Journal of physiology. 1993;468:73-83.
41. Wang X, Karlsson JO, Zhu C, Bahr BA, Hagberg H, Blomgren K. Caspase-3 activation after neonatal rat cerebral hypoxia-ischemia. Biology of the neonate. 2001;79(3-4):172-9.
42. Ek CJ, Habgood MD, Dziegielewska KM, Potter A, Saunders NR. Permeability and route of entry for lipid-insoluble molecules across brain barriers in developing Monodelphis domestica. The Journal of physiology. 2001;536(Pt 3):841-53.
43. Ryu HW, Lim W, Jo D, Kim S, Park JT, Min JJ, et al. Low-Dose Evans Blue Dye for Near-Infrared Fluorescence Imaging in Photothrombotic Stroke Model. International journal of medical sciences. 2018;15(7):696-702.
44. Saria A, Lundberg JM. Evans blue fluorescence: quantitative and morphological evaluation of vascular permeability in animal tissues. Journal of neuroscience methods. 1983;8(1):41-9.
45. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nature methods. 2012;9(7):676-82.
46. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature methods. 2012;9(7):671-5.
47. Mottahedin A, Blondel S, Ek J, Leverin AL, Svedin P, Hagberg H, et al. N-acetylcysteine inhibits bacterial lipopeptide-mediated neutrophil transmigration through the choroid plexus in the developing brain. Acta neuropathologica communications. 2020;8(1):4.
48. Koto T, Takubo K, Ishida S, Shinoda H, Inoue M, Tsubota K, et al. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol. 2007;170(4):1389-97.

49. Kumar A, Mittal R, Khanna HD, Basu S. Free radical injury and blood-brain barrier permeability in hypoxic-ischemic encephalopathy. Pediatrics. 2008;122(3):e722-7.

50. Dobrogowska DH, Vorbrodt AW. Immunogold localization of tight junctional proteins in normal and osmotically-affected rat blood-brain barrier. Journal of molecular histology. 2004;35(5):529-39.

51. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. The Journal of cell biology. 2003;161(3):653-60.

52. Raleigh DR, Boe DM, Yu D, Weber CR, Marchiando AM, Bradford EM, et al. Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function. The Journal of cell biology. 2011;193(3):565-82.

53. Tu XK, Yang WZ, Liang RS, Shi SS, Chen JP, Chen CM, et al. Effect of baicalin on matrix metalloproteinase-9 expression and blood-brain barrier permeability following focal cerebral ischemia in rats. Neurochemical research. 2011;36(11):2022-8.

54. Tang S, Xu S, Lu X, Gullapalli RP, McKenna MC, Waddell J. Neuroprotective Effects of Acetyl-L-Carnitine on Neonatal Hypoxia Ischemia-Induced Brain Injury in Rats. Developmental neuroscience. 2016;38(5):384-96.

55. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurgical focus. 2007;22(5):E4.

56. Jiao H, Wang Z, Liu Y, Wang P, Xue Y. Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood-brain barrier in a focal cerebral ischemic insult. Journal of molecular neuroscience : MN. 2011;44(2):130-9.

57. Shi S, Qi Z, Ma Q, Pan R, Timmins GS, Zhao Y, et al. Normobaric Hyperoxia Reduces Blood Occludin Fragments in Rats and Patients With Acute Ischemic Stroke. Stroke. 2017;48(10):2848-54.

58. Liu J, Jin X, Liu KJ, Liu W. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J Neurosci. 2012;32(9):3044-57.

59. Piontek J, Krug SM, Protze J, Krause G, Fromm M. Molecular architecture and assembly of the tight junction backbone. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2020;1862(7):183279.

60. Hill CA, Threlkeld SW, Fitch RH. Early testosterone modulated sex differences in behavioral outcome following neonatal hypoxia ischemia in rats. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. 2011;29(4):381-8.

61. Hill CA, Fitch RH. Sex differences in mechanisms and outcome of neonatal hypoxia-ischemia in rodent models: implications for sex-specific neuroprotection in clinical neonatal practice. Neurology research international. 2012;2012:867531.

62. Douglas-Escobar M, Weiss MD. Neonatal Biomarkers of Brain Injury. NeoReviews. 2013;14(10):e501-e12.
63. Chalak LF. Inflammatory Biomarkers of Birth Asphyxia. Clinics in perinatology. 2016;43(3):501-10.
64. Toorell H, Zetterberg H, Blennow K, Sävman K, Hagberg H. Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2018;31(18):2468-72.
65. Thorngren-Jerneck K, Alling C, Herbst A, Amer-Wahlin I, Marsal K. S100 protein in serum as a prognostic marker for cerebral injury in term newborn infants with hypoxic ischemic encephalopathy. Pediatric research. 2004;55(3):406-12.
66. Chalak LF, Sánchez PJ, Adams-Huet B, Laptook AR, Heyne RJ, Rosenfeld CR. Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy and outcomes in newborns receiving hypothermia therapy. The Journal of pediatrics. 2014;164(3):468-74.e1.
67. Gilland E, Bona E, Hagberg H. Temporal changes of regional glucose use, blood flow, and microtubule-associated protein 2 immunostaining after hypoxia-ischemia in the immature rat brain. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1998;18(2):222-8.
68. Mallard C, Vexler ZS. Modeling Ischemia in the Immature Brain: How Translational Are Animal Models? Stroke. 2015;46(10):3006-11.
69. Khong PL, Lam BC, Tung HK, Wong V, Chan FL, Ooi GC. MRI of neonatal encephalopathy. Clinical radiology. 2003;58(11):833-44.